KDIGO Releases New Guideline For Anemia In Chronic Kidney Disease
KDIGO released its 2026 Clinical Practice Guideline for the Management of Anemia in CKD, the first major update since 2012, incorporating new evidence on intravenous iron and hypoxia-inducible factor prolyl hydroxylase inhibitors.
Background
Anemia is a common and consequential complication of chronic kidney disease, associated with adverse outcomes and high health care costs. More than a decade had passed since the 2012 KDIGO anemia guideline, during which substantial new evidence accumulated on iron therapies, erythropoiesis-stimulating agents, and the newer HIF-PHI drug class, prompting a comprehensive update.
Key recommendations
The guideline's scope spans diagnosis and evaluation of anemia, use of iron to treat iron deficiency, use of erythropoiesis-stimulating agents and HIF-PHIs, and red blood cell transfusions in CKD. Commentary from European Renal Best Practice notes more proactive thresholds for intravenous iron, particularly in hemodialysis patients, and a continued preference for erythropoiesis-stimulating agents as first-line therapy given residual cardiovascular safety questions and methodological limitations of available HIF-PHI trials. Recommendations were developed using systematic reviews and the GRADE approach, supplemented by practice points where systematic review was not feasible.
Clinical implications
The update emphasizes comprehensive evaluation at diagnosis to identify causes of anemia beyond erythropoietin deficiency and an individualized approach to timing and type of treatment. Clinicians should account for regional regulatory differences in HIF-PHI approval and local context when implementing the recommendations, alongside special considerations such as inflammation and interactions with SGLT2 inhibitors highlighted in regional commentaries.
Category
KDIGO
Source
KDIGO
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.